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Although there has been a substantial decrease in infant mor-tality over the past 20 years1, the burden remains substantial, with the mortality rate of children under 5 years of age at 38 
per 1,000 live births in 20192, and 98% of recorded neonatal deaths 
now occurring in LMICs3. The World Health Organization (WHO) 
has declared neonatal sepsis a global concern4 and the burden of 
neonatal infectious diseases a major challenge. Effective manage-
ment of sepsis is not always possible when resources are limited3, 
and the steady increase of antimicrobial resistance (AMR) world-
wide further compromises sepsis management5,6.
Despite the burden of neonatal sepsis, accurate information on 
the causes and consequences of neonatal sepsis in LMICs is scarce4,6. 
Most studies in LMICs are from a single site, are of limited sample 
size, or lack accurate methods for sepsis diagnosis, pathogen iden-
tification and antibiotic susceptibility measurements7–10. In 2015 
and 2016, two multicentre neonatal sepsis studies in LMICs were 
published11,12. However, neither study combined antimicrobial sus-
ceptibility testing and whole-genome sequencing (WGS), making it 
difficult to determine the extent of genomic diversity (which would 
usually be done by comparing the lineages across geographical 
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Antimicrobial resistance in neonatal sepsis is rising, yet mechanisms of resistance that often spread between species via mobile 
genetic elements, ultimately limiting treatments in low- and middle-income countries (LMICs), are poorly characterized. The 
Burden of Antibiotic Resistance in Neonates from Developing Societies (BARNARDS) network was initiated to characterize the 
cause and burden of antimicrobial resistance in neonatal sepsis for seven LMICs in Africa and South Asia. A total of 36,285 neo-
nates were enrolled in the BARNARDS study between November 2015 and December 2017, of whom 2,483 were diagnosed with 
culture-confirmed sepsis. Klebsiella pneumoniae (n = 258) was the main cause of neonatal sepsis, with Serratia marcescens (n = 151), 
Klebsiella michiganensis (n = 117), Escherichia coli (n = 75) and Enterobacter cloacae complex (n = 57) also detected. We present 
whole-genome sequencing, antimicrobial susceptibility and clinical data for 916 out of 1,038 neonatal sepsis isolates (97 isolates 
were not recovered from initial isolation at local sites). Enterobacterales (K. pneumoniae, E. coli and E. cloacae) harboured multiple 
cephalosporin and carbapenem resistance genes. All isolated pathogens were resistant to multiple antibiotic classes, including 
those used to treat neonatal sepsis. Intraspecies diversity of K. pneumoniae and E. coli indicated that multiple antibiotic-resistant 
lineages cause neonatal sepsis. Our results will underpin research towards better treatments for neonatal sepsis in LMICs.
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areas) and resistance. The studies that have taken this approach 
were of single sites and often used WGS to investigate specific 
outbreaks13–16.
In LMICs, the epidemiology of early-onset sepsis (EOS) and 
late-onset sepsis (LOS) is not well defined3, unlike in high-income 
countries, where group B Streptococcus is usually considered the 
main cause of EOS17. A systematic review of the causes of blood 
culture-positive neonatal sepsis in Sub-Saharan Africa by Okomo 
et al.18 found that Klebsiella species, Escherichia coli, Enterobacter 
species and Pseudomonas species accounted for 38% of cases. Other 
single-site reports showed concordant findings9,11,12,19. However, 
these studies did not specifically determine whether certain species, 
or sequence type (ST) groups, are more likely to harbour resistance 
or virulence determinants, how this compares between different 
geographical areas and whether there is any relation to sepsis onset 
or outcome.
Burden of Antibiotic Resistance in Neonates from Developing 
Societies (BARNARDS; www.barnards-group.com) is a network of 
12 clinical study sites in four African (Ethiopia, Nigeria, Rwanda 
and South Africa) and three South Asian countries (Bangladesh, 
India and Pakistan). The aim of the BARNARDS study is to assess 
the burden of AMR in neonates in these LMIC. Here, we report on 
the isolation and characterization of Gram-negative bacteria (GNB) 
causing neonatal sepsis in seven LMICs, including their AMR pro-
files. We report associations between phenotypic and genotypic data 
and sepsis onset and mortality following biological sepsis (MFBS). 
We also analyse whole-genome sequences from isolates that cause 
neonatal sepsis.
Results
Enrolment in BARNARDS and isolation of pathogenic bacte-
ria. The numbers of neonates recruited, clinically diagnosed with 
sepsis and with a confirmation of sepsis by positive blood culture 
are outlined in Fig. 1. Of 36,285 infants ≤60 d old (termed herein 
as neonates) enrolled in the BARNARDS study from November 
2015 to December 2017, 2,483 had culture-confirmed sepsis. All 12 
clinical sites used the same criteria for clinical diagnosis of sepsis 
(Supplementary Fig. 1). We found that cases were mainly EOS for 
both sites in Pakistan, one site in Bangladesh (BC; see Methods for 
definitions of all two-letter site abbreviations) and the single site in 
Ethiopia. In Nigeria, India and South Africa, there were mainly LOS 
cases. In Rwanda, neonatal sepsis cases were equally split between 
EOS and LOS (Fig. 2).
Automated blood culture systems were used to detect microbial 
growth, with 2,620 microbial isolates recovered. These 2,620 iso-
lates comprised 1,266 Gram-positive bacteria (GPB) isolates, 1,038 
GNB isolates, 22 fungal isolates and 294 unassigned isolates (Fig. 1). 
The methods for collection and identification were standardized 
across all sites, with equipment and reagents purchased from uni-
form suppliers. The primary aim of the BARNARDS study was 
to characterize the extent of β-lactam resistance in GNB causing 
clinically diagnosed sepsis in infants <60 d old (see Supplementary 
Figs. 2 and 3). However, at month 17 (during a BARNARDS 
network event), we anecdotally noted high rates of isolation of 
Staphylococcus species and therefore collected all of these isolates 
for analysis (to be reported elsewhere). Of 1,038 isolates, 916 GNB 
were analysed using WGS. For 122 isolates, identification beyond 
a Gram stain was not possible because the isolate was lost and/or 
purification for DNA extraction was unsuccessful (Fig. 1).
In total, 58 different species of GNB were identified across all 
sites by WGS (Supplementary Table 1), including K. pneumoniae 
(n = 258), Serratia marcescens (n = 151), Klebsiella michiganensis 
(n = 117), Enterobacter species (n = 80), E. coli (n = 75), Burkholderia 
species (n = 61), Acinetobacter species (n = 49), Pseudomonas  
BC
n = 1,772
BK
n = 1,707
ES
n = 4,828
IN
n = 1,160
NK
n = 7,319
NN NW PC PP RK RU ZAT
n = 1,902 n = 2,359 n = 504 n = 7,945 n = 2,255 n = 1,222 n = 3,312
Neonates enrolled
(n = 36,285)
Neonates clinically
diagnosed (n = 9,874)
Neonates with culture-confirmed
sepsis (n = 2,483) and total
number of isolates recovered
from blood cultures, respectively
Sepsis isolates with missing
clinical data for sepsis onset
and outcome, respectively
n = 1,286 n = 341 n = 1,020 n = 72 n = 1,640 n = 648 n = 189 n = 124 n = 2,900 n = 703 n = 340 n = 611
n = 192, 195 n = 19, 19 n = 443, 330 n = 21, 20 n = 315, 263 n = 228, 234 n = 62, 55 n = 37, 48 n = 767, 805 n = 240, 231 n = 65, 61 n = 94, 114
n = 7, 56 n = 0, 3 n = 9, 52 n = 0, 7 n = 6, 33 n = 11, 1
BB isolates phenotypically identified on sites
(n = 2,701)
GPB BB isolates
(n = 1,266)
Staphylococcus
species (n = 271)
Other GPB
(n = 25)
No ID
(n = 970)
GNB Enterobacteriaceae
(n = 737)
GNB
non-Enterobacteriaceae (n = 179)
WGS
n = 916
MIC analysis
n = 885
Not
recoverable
(n = 122)
GNB BB isolates
(n = 1,038)
GNB BB isolates
recoverable in
United Kingdom (n = 916)
This study
Fungus BB isolates
(n = 22)
ND BB isolates
(n = 294)
Excluded contaminants
(n = 81)
n = 2, 0 n = 6, 3 n = 190, 343 n = 2, 0 n = 1, 1 n = 17, 62
Fig. 1 | Flow chart detailing the enrolment of neonates and incidence of sepsis (both clinically diagnosed and confirmed by culture) per site. The numbers 
of neonates with missing clinical data for the onset and outcome of sepsis are shown per site. The numbers of isolates collected from neonatal blood 
cultures are shown per site, with a breakdown by preliminary characterization (as determined by Gram stain) in the flow chart below. The final numbers of 
isolates included for analysis are highlighted in orange. BB, baby blood; ID, identification (of species); ND, not determined.
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species (n = 36) and Ralstonia mannitolilytica (n = 21) (Fig. 2). 
Among the GNB characterized herein, 401 were Klebsiella, with six 
species identified: K. pneumoniae, K. variicola, K. quasipneumoniae, 
K. aerogenes, K. oxytoca and K. michiganensis (Supplementary 
Fig. 4). Burkholderia cenocepacia, K. michiganensis, R. mannitolilyt-
ica and S. marcescens were mainly isolated from samples obtained 
from single sites in Pakistan, Nigeria and Bangladesh (Fig. 2).
Overall, R. mannitolilytica, K. michiganensis, Burkholderia spe-
cies and Pseudomonas species caused more cases of EOS than other 
species (Supplementary Table 2 and Supplementary Fig. 5). Of note, 
similar proportions of fatal sepsis cases were caused by GNB on each 
continent (92/353 cases in Africa (21%) and 118/475 cases in Asia 
(20%)). We found that Burkholderia species or K. michiganensis sep-
sis infections were the most likely to be fatal (Supplementary Table 
2 and Supplementary Fig. 5). However, there was a large proportion 
of missing data from certain clinical sites (due to data collection and 
entry error; Fig. 1), which limited the strength of conclusions.
Interspecies and intraspecies diversity across clinical sites. To 
understand the extent of inter- and intraspecies diversity, we aimed 
to perform WGS on all GNB. Multilocus sequence typing (MLST) 
was used primarily as an unambiguous tool to examine bacterial 
relatedness. As MLST can be performed easily via PCR of house-
keeping genes, in addition to in silico MLST via WGS, assessing 
relatedness via this tool (where applicable) provides a dataset that 
can be extrapolated to existing data on neonatal sepsis where WGS 
may not be available.
MLST revealed substantial intraspecies diversity, and 40 pre-
viously unknown STs were assigned in 12 species (Table 1 and 
Supplementary Table 2). Fourteen STs were assigned in the Klebsiella 
genera (Table 1), including all three K. aerogenes STs (all from 
Africa; n = 2 from Nigeria and n = 1 from South Africa; ST194–196). 
K. michiganensis was mainly ST180 (from PP in Pakistan; Table 1). 
Such low ST diversity and close phylogenetic relatedness, as shown 
by the core genome phylogeny (Supplementary Fig. 6), warrant 
further investigation. Similarly, we noticed that a single, previously 
unknown, B. cenocepacia ST (ST1621), also from PP, was dominant 
(Table 1 and Supplementary Fig. 7). B. cenocepacia ST1621 from 
PP and the S. marcescens isolates from BC were indistinguishable 
during core genome analysis (Supplementary Figs. 7 and 8). All 
local-level clusters will be studied further.
Enterobacter cloacae complex isolates were identified belonging 
to E. cloacae, E. hormaechei, E. kobei, E. asburiae and E. ludwigii. 
In total, seven different Enterobacter species (n = 80) with 28 STs 
were identified. The majority of Enterobacter species were found in 
Pakistan (n = 39), Nigeria (n = 19) and Rwanda (n = 14) (Fig. 1 and 
Supplementary Fig. 9). ST171 was common across sites in Africa 
and Asia; however, ST346 was only detected in Rwanda, ST523 was 
only detected in Pakistan and ST850 was only detected in Nigeria. 
Within Enterobacter species, 13 STs were assigned (Table 1) to E. 
cloacae, E. hormaechei and E. ludwigii isolates.
Acinetobacter species were recovered from ten out of 12 clinical 
sites in both Africa and South Asia, and 38 out of 49 (78%) were 
Acinetobacter baumannii. Of these, 17 out of 38 (45%) belonged to 
international clones (Pasteur MLST) ST1 and ST2 (Supplementary 
Tables 1 and 2).
AMR of pathogens causing neonatal sepsis. One aim of the 
BARNARDS study was to describe the AMR profiles of pathogens 
causing neonatal sepsis. For this, we performed agar dilution to 
determine the minimum inhibitory concentrations (MICs) of 19 
antibiotics, including the current recommended first-line empirical 
77
92 7
150
39
58
22
14
375
20
14
170
Not reported deceased 
Deceased
LOS
EOS
ND 118 475
Outcome of sepsis
92 353
Outcome of sepsis
BC
BK
ES
IN
NK
NN
NW
PC
PP
RK
RU
ZAT
0 100 200 300
Number of GNB sepsis cases
Si
te
Final species ID
Acinetobacter species
Burkholderia species
Enterobacter species
E. coli
K. michiganensis
K. pneumoniae
K. quasipneumoniae
Pseudomonas species
R. mannitolilytica
Serratia species
Fig. 2 | World map showing the BARNARDS study clinical site locations. The study sites are indicated by coloured squares. The African sites were 
located in Ethiopia (ES (green)), Nigeria (NK (cyan), NN (light blue) and NW (dark blue)), Rwanda (RK (dark purple) and RU (light purple)) and South 
Africa (ZAT; olive). The Asian sites were located in Bangladesh (BC (dark pink) and BK (light pink)), India (IN (orange)) and Pakistan (PC (peach) and 
PP (burgundy)). The numbers next to each clinical site location represent the total number of GNB identified. Inset: the stacked bar graph shows the 
distribution of the top ten GNB species recovered from blood cultures at the local sites. The onset of neonatal sepsis (EOS, LOS or ND) for GNB per clinical 
site is represented as a pie chart. The outcome of neonatal sepsis is shown for each continent.
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treatments for neonatal sepsis, as well as carbapenems (the inci-
dence of carbapenem-resistant GNB is increasing at an alarming 
rate), on 885 GNB (31 isolates were not recovered following storage 
at −80 °C after genomic DNA extraction for WGS; Supplementary 
Table 2 lists the isolates recoverable for WGS and/or MIC testing). 
Current data in LMICs focus on profiling AMR within certain spe-
cies only, and are therefore not exhaustive across all pathogens caus-
ing sepsis.
GNB (n = 885) were resistant to ampicillin (95%), cefotax-
ime (83%) and ceftriaxone (80%), whereas they were sensitive to 
meropenem (13%), imipenem (15%) and tigecycline (16%) (Fig. 
3a). The MICs required to inhibit the growth of 50% of organisms 
(that is, MIC50 values) of piperacillin/tazobactam, carbapenems 
(imipenem, meropenem and ertapenem), amikacin, fosfomycin, 
quinolones (ciprofloxacin and levofloxacin) and colistin were lower 
than their resistance breakpoints. The MIC90 values of all antibiotics 
tested were higher than their resistance breakpoints, with the excep-
tion of tigecycline, for which the MIC90 was lower than the epide-
miological cut-off value for Providencia and Proteus species20,21.
Overall, GNB isolates resistant to at least one of the cephalo-
sporins tested were less likely to cause LOS than EOS (P = 0.017; 
odds ratio (OR) = 0.63; 95% confidence interval (CI) = 0.43–0.92; 
Supplementary Table 3). For the statistical analysis, the outcome 
measurement was MFBS (deceased as response, alive as refer-
ence). Concomitant resistance to the three cephalosporins tested 
versus isolate susceptibility to all produced an odds ratio of 0.626; 
95% CI 0.426–0.918; P = 0.017. In this way, concomitant resis-
tance to the three cephalosporins tested among GNB isolates was 
less likely among infants who stayed alive compared to those who 
were deceased.
As a marker of extended-spectrum β-lactamase antibiotic resis-
tance gene (ARG), blaCTX-M-15 was inspected. It was detected in at 
least nine species (n = 523 isolates) and found in isolates from all 
study sites. We also screened genomes for genes coding for carbape-
nem resistance (blaNDM, blaOXA-48-like variants and blaKPC). There 
were 146 single carbapenemase genes in ten species (n = 128 iso-
lates), and two carbapenem resistance gene homologues were pres-
ent in 24 isolates. blaNDM-1 (n = 90; Bangladesh, n = 23; India, n = 6; 
Table 1 | STs for the most commonly identified species with a recognized MLST scheme
Species Isolates 
characterized by 
WGSa
Number identified per 
clinical siteb
Number of 
STs found
Prominent STs STs predominantly found 
in specific clinical sites
Previously 
unknown STs
A. baumannii complex 41 (38 ABA and 3 
ANO)
BC (n = 8), BK (n = 2), 
ES (n = 7), IN (n = 3), NK 
(n = 3), PC (n = 1), PP 
(n = 8), RK (n = 2), RU 
(n = 3) and ZAT (n = 3)
15 ST1, ST2, ST575 
and ST1106
ST2 (BC) and ST1106 
(PP)
ST1326 and 
ST1327
B. cenocepacia 56 BC (n = 1), PC (n = 1) and PP 
(n = 54)
5 ST1621 ST1621 (PP) ST1621 and 
ST1623
E. coli 75 BC (n = 3), ES (n = 11), IN 
(n = 2), NK (n = 15), NN 
(n = 7), NW (n = 1), PC 
(n = 3), PP (n = 10), RK 
(n = 15), RU (n = 2) and ZAT 
(n = 6)
37 ST10, ST69, ST131, 
ST410 and ST517
ST410 (PC) and ST517 
(RK)
ND
E. cloacae complex 78 (1 EAS, 57 ECL, 
18 EHO, 1 EKO and 
1 ELU)
BC (n = 2), NK (n = 7), NN 
(n = 9), NW (n = 1), PP 
(n = 39), RK (n = 14), RU 
(n = 5) and ZAT (n = 1)
34 ST84, ST93, 
ST171, ST346, 
ST523 and ST980
ST84 (PP), ST93 (PP), 
ST171 (PP), ST346 (RK), 
ST523 (PP) and ST980 
(RK)
ST1236 and 
ST1238–ST1248
K. michiganensis/ K. 
oxytoca
122 (117 KMI and 
5 KOX)
ES (n = 5), PC (n = 4), PP 
(n = 111) and RK (n = 2)
5 ST180 ST180 (PP) ST268 (KMI) 
and ST243–
ST244 (KOX)
K. pneumoniae 258 BC (n = 17), BK (n = 2), 
ES (n = 95), IN (n = 5), 
NK (n = 16), NN (n = 37), 
NW (n = 4), PC (n = 2), PP 
(n = 42), RK (n = 15), RU 
(n = 7) and ZAT (n = 16)
57 ST15, ST35, ST37, 
ST39, ST218, 
ST307, ST348, 
ST443, ST464 
and ST985
ST15 (PP), ST35 (ES), 
ST37 (ES), ST218 (ES), 
ST307 (RK), ST442 
(NN), ST464 (NN) and 
ST985 (ES)
ST4008, 
ST4410 and 
ST4411
K. quasipneumoniae 13 BC (n = 6), BK (n = 1), ES 
(n = 1), NK (n = 2), NN 
(n = 2) and PP (n = 1)
10 ST4405 ST4405 (BC) ST4405–
ST4407 and 
ST4409
K. variicola 5 BC (n = 1), PP (n = 1), RK 
(n = 2) and RU (n = 1)
5 ND ND ST4404 and 
ST4412–
ST4414
P. aeruginosa 23 BC (n = 1), BK (n = 4), IN 
(n = 1), NK (n = 2), NN 
(n = 3) PC (n = 1), PP (n = 9) 
and RK (n = 2)
14 ST3235, ST1285 
and ST3311
ST1285 (BK) and ST3311 
(PP)
ST3311
Salmonella enterica 7 NK (n = 6) and NN (n = 1) 4 ST313 ST313 (NK) ND
aNumbers of isolates characterized. For complexes, a breakdown by species is given. bNumbers of isolates from each clinical site. ABA, A. baumannii; ANO, A. nosocomialis; EAS, Enterobacter asburiae; ECL, E. 
cloacae; EHO, Enterobacter hormaechei; EKO, Enterobacter kobei; ELU, Enterobacter ludwigii; KMI, K. michiganensis; KOX, K. oxytoca.
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Nigeria, n = 16; Pakistan, n = 43; Rwanda, n = 1; South Africa, n = 1) 
and blaNDM-5 (n = 3; Bangladesh, n = 1; India, n = 1; Nigeria, n = 1) 
were mainly detected in clinical sites in South Asia, whereas blaNDM-7 
was predominantly recovered from Nigeria and Pakistan (n = 19; 
Bangladesh, n = 1; Nigeria, n = 11; Pakistan, n = 7) (Fig. 3b). In 79 
GNB, blaCTX-M-15 plus blaNDM and/or a blaOXA-48-like variant were 
found. In total, 30 GNB carried a variant of the blaOXA-48-like fam-
ily, with blaOXA-181 being the most frequent (Pakistan, n = 22; India, 
n = 1; Fig. 3b). blaOXA-232 was only found in Bangladesh (n = 5), and 
the two isolates carrying blaOXA-48 (one K. michiganensis and one 
S. marcescens) were from PP. blaVIM was found in three Pseudomonas 
aeruginosa isolates (Bangladesh, n = 2 (BC, n = 1; BK, n = 1); India, 
n = 1). Both blaVIM variants from Bangladesh were blaVIM-2, whereas 
the variant detected in India was blaVIM-6.
In Enterobacter species, blaCTX-M-15 was found in isolates recov-
ered from both Africa and South Asia (n = 19; Africa, n = 16; South 
Asia, n = 3); however, Enterobacter containing carbapenemase genes 
(n = 18) were largely recovered from South Asia (South Asia, n = 16; 
Africa, n = 2). Five Acinetobacter (A. baumannii, n = 3; Acinetobacter 
bereziniae, n = 1; Acinetobacter nosocomialis, n = 1) were found to 
have blaNDM-1 (Africa, n = 2; South Asia, n = 3) (Fig. 3b). Additionally, 
we found blaOXA-23 within 20 A. baumannii isolates.
The total number of ARGs possessed by each bacterial isolate 
is shown in Supplementary Table 4. For each ARG increase among 
E. cloacae, we observed a 13.2% decrease in the likelihood of neo-
nates having LOS (P = 0.016; 95% CI = 0.77–0.97). No other associa-
tions between ARG and onset were found (Supplementary Table 3).
Worryingly, we found that 529 (60%) of the GNB isolates tested 
were resistant to the first-line empirical treatment for neonatal sep-
sis (both ampicillin and gentamicin).
Plasmids and carbapenemase genes. As many ARGs are carried on 
mobile genetic elements such as plasmids, we searched for plasmid 
replicon types in isolates from the different geographical areas and, 
where possible, analysed linkages between plasmid type and the 
carriage of specific carbapenemase genes. We detected 1,124 plas-
mids with 45 inc gene variants, which we categorized into 18 plas-
mid groups. From these, 1,093 were found within E. coli (n = 169), 
K. pneumoniae (n = 623), K. michiganensis (n = 142), K. quasipneu-
moniae (n = 28), Enterobacter species (n = 87) and S. marcescens 
(n = 44) (Fig. 4). There were 12 plasmid types found within the 
seven S. enterica isolates, seven among Citrobacter species and five 
among K. variicola isolates.
Within the six dominant plasmid carriers (Fig. 4), the most 
frequently detected inc type was IncFIB, with 255 out of 440 hits 
within K. pneumoniae genomes. blaNDM-1 was found in IncA/C2 
plasmids from K. pneumoniae and Enterobacter species from PP, as 
well as in IncFIB plasmids from K. pneumoniae from India (Fig. 4  
and Supplementary Fig. 10). We found IncX3 plasmids carrying 
blaNDM-5 in K. pneumoniae from NK, Nigeria, and multiple blaNDM-7 in 
K. pneumoniae and Enterobacter species from Nigeria and Pakistan 
(Fig. 4 and Supplementary Fig. 10). Col plasmid types were identified 
within 82 genomes. We found ColKP3 plasmids carrying blaOXA-181 or 
blaOXA-232 in isolates of three different species: E. coli, K. pneumoniae 
and Enterobacter species (Fig. 4 and Supplementary Fig. 10).
Our bioinformatics analysis relied on the interrogation of 
short-read sequencing data; therefore, it was not possible to anal-
yse the genetic context to link carbapenemase genes and inc type 
for all genomes. Instead, a representative genome of each species/
ST with the largest contig carrying the carbapenemase gene was 
chosen to maximize the analysis of other genetic material present, 
including the inc gene (n = 9; Supplementary Fig. 10). This analysis 
demonstrated cases where the same carbapenemase gene variant 
was detected in the same plasmid type across different GNB, sug-
gesting that successful dissemination and acquisition within mul-
tiple species may be occurring. We also found cases where the same 
carbapenemase ARG was detected in multiple different plasmids, 
furthermore evidencing the spread of AMR.
Characterization of K. pneumoniae. K. pneumoniae is an impor-
tant cause of neonatal sepsis in LMICs; however, there are few data 
analysing this species beyond antimicrobial susceptibility testing. 
Here, we have shown that K. pneumoniae was the most frequently 
identified GNB; therefore, the genomic diversity of this collection 
was scrutinized to contextualize these isolates, both within this 
study collection and within previously known collections15,16,22,23. 
K. pneumoniae (n = 258) was found at all clinical sites (Figs. 1 and 5, 
Supplementary Table 2 and Supplementary Fig. 4)—predominantly, 
Ethiopia (n = 95), Nigeria (n = 57) and Pakistan (n = 44).
Genomics analysis within both the global15,16,22 (Fig. 5a; see 
Supplementary Table 5 for literature search inclusion criteria) and 
neonatal sepsis context23 (Fig. 5b) revealed high diversity of K. pneu-
moniae, with 156 STs from 17 countries spanning five continents. 
BARNARDS isolates clustered with previously reported neonatal 
isolates, including ST45, ST48 and ST348 (refs. 15,22,23), but we also 
revealed distinct and new genetic lineages. The major AMR-related 
K. pneumoniae clades in Asia (ST11) and Europe (ST147 and 
ST307)24 were also identified in this study. We only found ST307 
in Rwanda (n = 6) and Nigeria (n = 2). However, ST258, a North 
American clade frequently associated with blaKPC25,26, was absent, 
which accords with the absence of blaKPC in this study. We did, 
however, detect one blaKPC-2 gene in a K. quasipneumoniae from 
Bangladesh (Supplementary Fig. 10). While other studies have sug-
gested that blaKPC K. pneumoniae causes neonatal sepsis, especially 
during nosocomial outbreaks25, there is currently little evidence 
from countries in Africa or South Asia.
BARNARDS’ K. pneumoniae were disseminated throughout the 
global phylogeny, with 57 STs (Table 1 and Fig. 5a). ST35 and ST37 
were predominantly found in Ethiopia (n = 38/39 and n = 29/30, 
respectively). We found four ST35 K. pneumoniae from other neo-
natal sepsis publications; however, these sit on a distinct branch in 
the core genome phylogeny (Fig. 5b) and were more closely related 
to the single ST35 isolated from RU, Rwanda. ST15 isolates were 
largely isolated from Pakistan and all carried both blaNDM-1 and 
blaOXA-181 (n = 22/27; Fig. 5b). ST15 was almost exclusively found 
at the South Asian clinical sites, with a single ST15 found at NN, 
Nigeria. ST442 (n = 6) and ST464 (n = 8) were only found in NN and 
all isolates contained either blaNDM-1 (ST442) or blaNDM-7 (ST464).
Multiple different capsule types (n = 47 KL loci and n = 12 O 
loci) were identified in silico. ST15 isolates in Pakistan (n = 23) and 
India (n = 1) were all the O1v1:KL112 serotype, whereas single ST15 
isolates in Bangladesh and Nigeria had different serotype combi-
nations of O3b:KL38 and O1v1:KL48, respectively. Similarly, the 
ST35 isolates from Ethiopia were all O1v2:KL108, whereas K. pneu-
moniae from RU in Rwanda were O2v1:KL113. Of the eight ST348 
isolates, of which seven were from South Africa and one was from 
Fig. 5 | Core genome characterization of K. pneumoniae isolates. a, Five-hundred-and-fifty-nine isolates incorporating a global collection23. Blue shading 
indicates K. pneumoniae isolates from the BARNARDS collection. The branch labels are coloured according to country of origin. b, Detailed core genome 
characterization of 309 K. pneumoniae isolates (n = 258 BARNARDS). Yellow shading indicates isolates from other studies15,22 causing neonatal sepsis. The 
outermost rings represent infant outcome (orange) and onset of sepsis (green), followed by the ST, where asterisks represent previously unknown STs. The 
leaf labels are the code names (coloured according to the study site) of isolates. The branch symbols in the centre denote the carriage of carbapenemase 
ARGs (blaNDM variants (circles) and blaOXA-48 group variants (squares)). NA, not applicable.
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NW (Nigeria), all were O1v1:KL62 and all contained the yersinia-
bactin virulence gene.
In total, 115 isolates had a virulence score of 1, 3 or 4, indicat-
ing the presence of yersiniabactin and/or aerobactin/salmochelin 
virulence genes (see the Kleborate repository27 and Source Data 
Fig. 5). The odds of LOS were 89% lower for infants with sepsis due 
to K. pneumoniae who had a virulence score of 3 or 4 compared with 
those with a score of 0 (P = 0.04; 95% CI = 0.014–0.90). Additionally, 
the odds of the outcome deceased were 14 times higher for infants 
with sepsis due to K. pneumoniae who had a virulence score of 3 
or 4 compared with those with a virulence score of 0 (P = 0.001; 
95% CI = 2.76–68.77; Supplementary Table 3). These results sug-
gest that these genes may be involved in quicker onset and MFBS. 
Alternatively, they may reflect transmission of distinct isolates from 
the mother’s microbiota6 and from the clinical environment.
K. pneumoniae harboured multiple β-lactamase genes (Source 
Data Fig. 5). blaCTX-M-15 was found in 220 out of 258 isolates across 
diverse STs and at all clinical sites, representing 42% (220/523) of total 
blaCTX-M-15-positive GNB. Over one-quarter (26%; 69/258) harboured 
a variant of blaNDM (Figs. 4b and 5b). blaNDM-1 (n = 15), blaNDM-5 (n = 1) 
and blaNDM-7 (n = 9) were found in Nigeria (mainly NN), whereas 
blaNDM-1 was the dominant variant in South Asia (Fig. 4b).
All K. pneumoniae were resistant to ampicillin, cefotaxime, cef-
triaxone and ceftazidime. K. pneumoniae concomitantly resistant to 
the three cephalosporins tested (n = 255) were significantly more 
likely to cause EOS than LOS (P = 0.045; OR = 0.41; 95% CI = 0.17–
0.98; Supplementary Table 3). Also, 144 isolates had >15 ARGs. 
For each additional ARG, we observed a 5.7% (P = 0.028; 95% 
CI = 0.89–0.99) decrease in the odds of neonates having LOS com-
pared to EOS.
Collectively, this analysis reveals a large degree of intraspe-
cies diversity within K. pneumoniae pathogens causing neonatal 
sepsis in LMICs. While certain ST groups previously shown to be 
dominant in particular geographic regions were found during the 
BARNARDS study, we also detected several different ST groups car-
rying different carbapenemase ARGs and virulence determinants.
Characterization of E. coli. E. coli has previously been reported 
as a dominant GNB cause of neonatal sepsis across many differ-
ent LMICs18. In light of this, we aimed to further characterize the 
BARNARDS E. coli isolates and to compare the results with existing 
WGS datasets (Supplementary Table 5 displays the literature search 
inclusion criteria). The 2014 enterotoxigenic E. coli collection28 dis-
played large diversity and, when analysed with the BARNARDS 
dataset, 90 STs across four continents and 21 countries were 
detected (Fig. 6a). The E. coli analysed herein fell within four main 
clades of the extended phylogeny. The greatest numbers of E. coli in 
the BARNARDS study (n = 75) were in Nigeria (n = 23; 31%) and 
Rwanda (n = 17; 23%), although E. coli neonatal sepsis was identi-
fied in 11 of the 12 clinical sites (excluding BK, Bangladesh). A phy-
logenetic analysis of BARNARDS E. coli revealed four main groups, 
each containing multiple clades (Fig. 6b), with 37 STs detected. 
ST10 (n = 9), ST131 (n = 6), ST410 (n = 5) and ST69 (n = 4) were 
the most common. In the Mentzer et al.28 collection, ST10 was 
found in five countries across Africa, Asia and South America. Of 
the nine ST10 E. coli characterized here, seven were from clinical 
sites within Africa (Ethiopia, n = 1; Nigeria, n = 5; Rwanda, n = 1) 
and two were from PP, Pakistan. Although all ST10 E. coli belonged 
to the same phylotype (that is, group A), each isolate had a differ-
ent O:H serotype profile and the phylogenetic tree (Fig. 6b) shows 
variability in the branch length, indicating genomic diversity within 
this ST group. Generally, we found highly variable O:H serotype 
classification (n = 57 O:H combinations), irrespective of the ST 
or phylogroup (A–F) (Source Data Fig. 6). Of the phylotypes, A 
(n = 22), B1 (n = 15) and B2 (n = 18) were the most common.
β-lactam and aminoglycoside ARGs were most commonly found 
in the South Asian isolates, with the exception of blaCTX-M-15, which 
was also detected in E. coli from Africa. In total, 21 E. coli harboured 
blaCTX-M-15 and belonged to a variety of STs, including ST131, ST405, 
ST410, ST10 and ST167. Carbapenemase genes were detected in 
only three out of 75 E. coli. The three isolates were from South Asia, 
and all concomitantly carried blaCTX-M-15 plus blaNDM-5 (ST167; n = 2) 
or blaOXA-181 (ST410; n = 1).
No significant associations were found between phenotypic or 
genotypic AMR-related traits of E. coli and the clinical data assessed 
herein (Supplementary Table 3).
E. coli isolates were extremely diverse, suggesting that there are 
probably several important and worrisome lineages.
Discussion
In the BARNARDS study, we established a methodological frame-
work to capture and extensively characterize GNB species causing 
neonatal sepsis in LMICs. We isolated 916 isolates of GNB, char-
acterized them to species level, used WGS to probe genome com-
position and MLST to assess intra- and interspecies diversity, and 
documented extremely high rates of AMR.
Most of the Gram-negative isolates from neonates with sep-
sis were resistant to at least one β-lactam and one aminoglycoside 
(597/885; 67%), as has been reported previously for cohorts in 
India29 and 26 countries in Africa18. World Health Organization 
guidelines30 stipulate ampicillin plus gentamicin as the first line of 
empirical treatment for neonatal sepsis and third-generation cepha-
losporins as the second line of treatment. Of note, many of the blood 
culture isolates from our study were resistant to both lines of treat-
ment, meaning that treatment options are unlikely to be curative.
The identification of 58 different GNB species suggests that the 
aetiology of neonatal sepsis is complex. We report multiple differ-
ent lineages causing infection within single species, many of which 
carry either resistant or putatively virulent mechanisms and several 
of which have previously been shown to cause neonatal sepsis (for 
example, ST35 and ST37 K. pneumoniae)23,31. The identification of 
high-risk clones, such as ST15 in K. pneumoniae32 and the global 
clones ST1 and ST2 in A. baumannii, which are notorious for nos-
ocomial infection33, indicates the spread and persistence of prob-
lematic lineages in LMICs. In addition, through our comprehensive 
analysis, we identified 40 previously unknown STs, suggesting that 
well-known and previously unidentified lineages/ST groups are 
both co-existing and evolving.
A limitation of our study was the inability to follow up all neo-
nates to 60 d (necessitating the exclusion of neonates who were 
lost to follow-up), which impacted our outcome data (Fig. 1). It is 
likely that additional local factors (such as the management of sep-
sis) contributed to mortality; therefore, we cannot attribute MFBS 
singularly to the presence/absence of genomic traits. Our statistical 
analyses were exploratory and should be interpreted as hypothesis 
generating only.
Fig. 6 | Core genome characterization of E. coli isolates. a, Three-hundred-and-sixty isolates incorporating a global collection28. Blue shading indicates 
E. coli isolates from the BARNARDS collection (n = 75). The branch labels are coloured according to country of origin. b, Detailed core genome 
characterization of 87 E. coli isolates (n = 75 BARNARDS). Yellow shading represents isolates from other studies16,22 causing neonatal sepsis. The colours 
on the right represent infant outcome (orange) and onset of sepsis (green), followed by the ST. The numbers and code names (coloured according to study 
site) of isolates are also given. The branch symbols denote the carriage of carbapenemase ARGs (blaNDM-5 (circles) and blaOXA-181 (squares). NF, not found.
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In summary, Klebsiella, E. coli and Enterobacter were the main 
GNB species responsible for sepsis in neonates. We report that 54% 
of isolated bacteria were resistant to at least one antibiotic within 
four to six classes of antibiotics, and observed widespread carriage 
of both resistance genes and virulence factors in GNB causing neo-
natal sepsis in LMICs. This large, observational study will inform 
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future research into effective antimicrobial therapies for neonatal 
sepsis, and may underpin improved infection control practices and 
could be useful in the development of vaccines for neonatal sepsis 
in LMICs.
Methods
Study design and processing of blood cultures at clinical sites. A prospective 
cohort study was conducted through the BARNARDS network consisting 
of 12 clinical sites in seven countries in Africa and South Asia (Chattogram 
Maa-O-Shishu Hospital, Chattogram (BC) and Kumudini Women’s Medical 
College, Mirzapur (BK) in Bangladesh; St. Paul’s Hospital Millennium 
Medical College, Addis Ababa (ES) in Ethiopia; the Division of Bacteriology, 
ICMR-National Institute of Cholera and Enteric Diseases, Kolkata (IN) in India; 
National Hospital Abuja, Abuja (NN), Wuse District Hospital, Abuja (NW) and 
Murtala Muhammad Specialist Hospital, Kano (NK) in Nigeria; Pakistan Institute 
of Medical Sciences, Islamabad (PP) and Bhara Kahu Rural Health Centre, Bhara 
Kahu (PC) in Pakistan; University Central Hospital of Kigali, Kigali (RU) and 
Kabgayi Hospital, Kabgayi (RK) in Rwanda; and Tygerberg Hospital, Cape Town 
(ZAT) in South Africa). Ethical approval was obtained from the local ethics 
committee at each site before the start of the study (Supplementary Table 6). 
Between November 2015 and December 2017, women in labour or immediately 
postpartum were recruited prospectively following consent, and their neonates 
were followed up for the first 60 d of life (at 3, 7, 14, 28 and 60 d of life) or until 
study withdrawal/death. Neonates admitted to clinical sites showing signs of sepsis 
were also enrolled. The BARNARDS sample collection workflow is shown in 
Supplementary Fig. 11. Although it was not strictly a neonatal population, during 
this study, we employed the term neonate for all enrolments, including those 
between 30 and 60 d post-birth.
Documentation detailing the parameters for clinically diagnosing sepsis is 
available in Supplementary Fig. 1. The standard operating procedures for the 
laboratory processing of blood cultures and subsequent identification of bacteria, 
which were followed by all clinical sites (following agreement between clinical 
partners before the start of enrolment), are shown in Supplementary Fig. 2. 
Laboratory reagents (Liofilchem)—importantly, both agar media and antibiotic 
discs (used at the clinical sites)—were standardized throughout the network. 
Bacterial identification performed at each site was confirmed by WGS at Cardiff 
University. Antimicrobial susceptibility testing was performed twice: initially, at the 
local sites to guide treatment using antibiotic discs; and then at Cardiff University 
using the agar dilution method to establish the MICs (details below). The collected 
clinical data included onset of sepsis (EOS or LOS) and patient outcome following 
biological sepsis. Neonates that were lost to follow up were categorized along 
with neonates confirmed alive as ‘not reported deceased’. For the purpose of this 
study, EOS and LOS were defined as sepsis occurring ≤72 h and >72 h after birth, 
respectively. If neonates showed clinical signs of sepsis at multiple time points 
within the first 60 d of life, additional blood cultures were analysed. All viable 
bacterial species were stored on charcoal swabs (Deltalab) for transport under 
UN3373 regulations to Cardiff University.
At Cardiff University, GNB isolates were plated onto chromogenic urinary 
tract infection media supplemented with vancomycin at 10 mg l−1 (Liofilchem) and 
incubated aerobically overnight at 37 °C. Isolates were identified using a Microflex 
LT MALDI-TOF MS (Bruker Daltonik) with α-cyano-4-hydroxycinnamic acid 
matrix (Sigma–Aldrich). Bacterial isolates were stored in TS/72 beads (Technical 
Service Consultants) at −80 °C and the original swabs were stored at 4 °C. MICs 
were determined by agar dilution for a panel of 19 antibiotics and interpreted 
according to the EUCAST guidelines20,21. E. coli ATCC 25922 and P. aeruginosa 
ATCC 27853 strains were used as quality controls for GNB tests. Supplementary 
Table 7 depicts the panels of antibiotics and additional control strains used. 
Supplementary Table 8 defines the EUCAST interpretations used. The MIC50 
and MIC90 values for each antibiotic was determined. The phenotypic metadata 
included the following AMR-related counts: carbapenem resistance (taken as 
resistance to ertapenem); methicillin resistance (taken as an oxacillin MIC > 2) 
and an AMR score (the number of antibiotics to which an isolate was resistant) 
(Supplementary Table 7).
WGS. A single bacterial colony was transferred into 1.8 ml LB broth and incubated 
at 37 °C and 180 r.p.m. for 18 h. Genomic DNA was extracted using a QIAamp 
DNA Mini Kit (Qiagen), with an additional RNAse step, on a QIAcube (Qiagen), 
and quantified using a Qubit Fluorometer 3.0. Genomic libraries were prepared 
using a Nextera XT V2 kit (Illumina) with bead-based normalization. A total of 
48 isolates were multiplexed per sequencing run to provide a depth of coverage 
of >15×. Paired-end WGS was performed on an Illumina MiSeq using the V3 
chemistry to generate fragment lengths of up to 300 base pairs (600 cycles).
Bioinformatics analyses. Bioinformatics analyses were performed using a 
high-performance computing cluster at Cardiff University (Advanced Research 
Computing at Cardiff (ARCCA)) and CLIMB (version 1.0)34. Paired-end reads 
(FASTQ) were subjected to quality control checks before downstream analysis. 
Trim Galore (version 0.4.3)35 was used to remove the Nextera adapter sequences 
and low-quality bases. Reports before and after read trimming were generated 
using FastQC (version 0.11.2)36 and collated using MultiQC (version 1.7)37. The 
mean read length and number of sequences provided on the MultiQC reports were 
used to determine the sequencing coverage. Paired-end reads were overlapped 
using Flash (version 1.2.11)38 and assembled into contigs using SPAdes (version 
3.9.0)39. The trimmed FASTQ reads were mapped to the contigs using BWA 
(version 0.7.15)40 and SAMtools (version 1.3.1)41. Pilon (version 1.22)42 was used 
to assess any misassemblies/errors in base calling in the resulting mapped BAM 
file. Final genome assembly metrics were generated using QUAST (version 2.1)43. 
Bacterial species were identified using both BLAST nt (version 2.2.25; https://blast.
ncbi.nlm.nih.gov/Blast.cgi; input = contigs)44 and PathogenWatch (version 3.13.10; 
https://pathogen.watch; input = contigs). MLST, virulence and plasmid genomic 
profiles were characterized using SRST2 (version 0.2.0)45 and the associated 
databases PlasmidFinder46 and VFDB47. Genomes were screened for ARGs using 
ABRicate (version 0.9.7)48 (databases NCBI49 and ResFinder50).
Novel alleles and novel ST profiles were submitted to BIGSdb (version 
1.25.1)51. The O:K locus profiles for all Klebsiella species were determined using 
Kaptive (version 0.7.0)52 and Kleborate (version 0.2.0; https://github.com/katholt/
Kleborate)27. The O:H serotype profiles for all E. coli isolates were determined 
using SerotypeFinder (version 2.0)53, and SeqSero (version 1.0)54 was used to 
determine serotypes for Salmonella. In silico E. coli phylotyping was performed 
using ClermonTyping (version 1.3.0)55. Genomes were annotated using Prokka 
(version 1.12)30. Strain relatedness analysis was performed using Roary (version 
3.12.0)56 to create a core genome alignment and FastTree (version 2.1.11) to 
generate maximum likelihood phylogenetic trees. Phylogenetic trees were 
mid-rooted, visualized and annotated using iTOL (version 5.7)57. The plasmid 
Sankey diagram was generated using the networkD3 package in R version 3.6.2. 
The immediate genetic context around carbapenemase genes was performed 
aligning outputs from ResFinder and PlasmidFinder (in ABRicate) with Mobile 
Element Finder (version 1.0.1) hosted by the Center for Genomic Epidemiology 
(https://cge.cbs.dtu.dk/services/MobileElementFinder/). The GBK annotation file 
from Prokka was then analysed for image production in Geneious Prime version 
2020.1.2.
Statistical analyses. Statistical associations between clinical outcomes (onset of 
sepsis (EOS/LOS) and MFBS (alive/deceased)) and phenotypical and genomic 
traits were explored using univariable logistic regression models with the Wald 
test in SPSS version 26. The outcomes for the analyses regarding sepsis onset were 
EOS and LOS and those for MFBS were alive and deceased. Depending on whether 
predictor variables were continuous (AMR or ARG) or categorical (resistance 
versus non-resistance to ampicillin and gentamicin, concomitant resistance 
versus non-concomitant resistance to the three cephalosporins tested, resistance 
to at least one of the three cephalosporins tested versus to none, resistance versus 
non-resistance to ertapenem (a marker for carbapenems resistance) or Klebsiella 
species virulence scores), they were treated as covariates or factors, respectively. For 
species group analyses, only groups with n = ≥50 isolates were included, except for 
B. cenocepacia isolates, which did not carry ARGs. Statistical significance was taken 
at P ≤ 0.05, and estimated ORs are presented along with 95% CIs.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Sequence reads have been submitted to the European Nucleotide Archive under 
project number PRJEB33565. Individual accession numbers and additional 
genomics data can be accessed in Supplementary Table 4 and the source data. 
The databases used for this study included VFDB (http://www.mgc.ac.cn/VFs/
download.htm), NCBI (https://github.com/tseemann/abricate/tree/master/db/
ncbi), ResFinder (https://github.com/tseemann/abricate/tree/master/db/resfinder), 
PlasmidFinder (https://bitbucket.org/genomicepidemiology/plasmidfinder/src/
master), MLST (https://github.com/tseemann/mlst/tree/master/db/pubmlst), 
MGE (https://bitbucket.org/mhkj/mge_finder/src/master/me_finder/), 
SerotypeFinder (https://bitbucket.org/genomicepidemiology/serotypefinder/src/
master) and SeqSero (http://www.denglab.info/SeqSero). Previously published 
datasets downloaded from the European Nucleotide Archive repository and used 
for comparative genomics analysis have the identifiers PRJEB2111, PRJEB2581 
and PRJEB20875. The following genomes were downloaded from NCBI: 
PHGE01000000–PHGR01000000, ATNW00000000 and ATNV00000000. Source 
data are provided with this paper.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection No software was used in the data collection. At the low middle income countries, research nurses completed questionnaires with the women 
approaching labor. These questionnaires were either transcribed onto paper, due to availability of resources/infrastructure, i.e. Internet 
access, and later uploaded into Bristol Online survey (BOS) or directly entered into BOS using a tablet device provided by the project.
Data analysis CLIMB (v1.0)  
Trimgalore (v0.4.3)  
fastqc (v0.11.2)  
MultiQC (v1.7)  
Flash (v1.2.11) 
 SPAdes (v3.9.0)  
BWA (v.0.7.15)  
samtools (v1.3.1) 
Pilon (v1.22) 
quast (v.2.1) 
Blast nt (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (v2.2.25) 
PathogenWatch (v.3.13.10; https://pathogen.watch) 
srst2 (v0.2.0) 
ABRicate (v0.9.7) 
BIGSbd (v1.25.1)  
Kaptive (v0.7.0) 
and Kleborate (v0.2.0) 
SerotypeFinder (v2.0)  
SeqSero (v1.0)  
ClermonTyping (v.1.3.0) 
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Prokka (v1.12) 
Roary (v3.12.0)  
FastTree (v2.1.11)  
iTOL (v5.7) 
networkD3 package, Rv3.6.2 
Geneious prime (2020.1.2) 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and 
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Sequences reads were submitted to the European Nucleotide Archive (ENA) and given the project number PRJEB33565. A list of individual accession numbers for 
916 Gram-negative bacteria can be found in the source data (to accompany figure 4,5 & 6). 
 
Databases used within this study:  
VFDB: http://www.mgc.ac.cn/VFs/download.htm 
NCBI: https://github.com/tseemann/abricate/tree/master/db/ncbi  
Resfinder: https://github.com/tseemann/abricate/tree/master/db/resfinder  
Plasmidfinder: https://bitbucket.org/genomicepidemiology/plasmidfinder/src/master 
mlst: https://github.com/tseemann/mlst/tree/master/db/pubmlst 
MGE: https://bitbucket.org/mhkj/mge_finder/src/master/me_finder/ 
Serotype finder: https://bitbucket.org/genomicepidemiology/serotypefinder/src/master  
Seqsero: http://www.denglab.info/SeqSero 
 
Previously published datasets downloaded from the ENA repository used for comparative genomics analysis: PRJEB2111, PRJEB2581 and PRJEB20875. Genomes 
were downloaded from NCBI: PHGE01000000-PHGR01000000, ATNW00000000, ATNV00000000.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size The sampling method was purposive and a formal sample size calculation was not conducted.  
 
Based on previous studies led by PI Professor Timothy Walsh (unpublished studies/awaiting publication), BARNARDS anticipated the 
enrollment level between 500-2000 neonates per clinical site for the duration of the study (depending on geographical location i.e. smaller 
rural site would have a smaller catchment area). With the anticipated sepsis rate (based on limited public accessible data), this would capture 
between 1,000-2,500 bacterial (both Gram-negative and Gram-positive) blood culture positive sepsis cases across seasonal variation with an 
estimated 1,000 Gram-negative sepsis cases.
Data exclusions The following exclusion criteria was pre-defined: the sepsis case infant/mother sampling pair was excluded in the case of a still born. Following 
this, data was retrospectively excluded based on the following criteria: 
- Incomplete questionnaire; missing multiple data points in the epidemiological dataset 
- Mother asked for infant withdrawal 
- Error/substantial inconsistencies in the questionnaire - laboratory sampling match up.
Replication N/A - Findings were not replicated as this manuscript is a full genomics characterisation of sepsis causing bacteria from low middle income 
countries (LMICs). All viable isolates eligible for sequencing were included into the analysis.
Randomization Randomization was not relevant to the study. All women approaching labor were (following consenst) enrolled onto the study. If the neonate/
infant presented with sepsis, the infant was also enrolled to allow a blood culture to be taken.
Blinding Blinding was not necessary for this study as we were characterizing all blood culture isolates along with the corresponding infant's clinical 
data.
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system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology and archaeology
Animals and other organisms
Human research participants
Clinical data
Dual use research of concern
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Human research participants
Policy information about studies involving human research participants
Population characteristics BARNARDS was a multi-site international prospective observational study incorporating two recruitment pathways: 
i.) Birth-Cohort: All mothers in labour admitted to clinical-sites were recruited prospectively and their infant(s) followed up 
until 60-days old or death. 
ii.) Infant Admissions (IA): Infant(s) admitted to clinical-sites showing signs of suspected sepsis in the first 60-days of life until 
60- days old or death. 
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For this study, isolates recovered from blood cultures were included into the characterisation of infant sepsis irrespective of 
cohort pathway. 
General population characteristics of the mothers' (oustide of the scope of this manuscript): <10% previously had stillbirth, 
approx. 25% were first time mothers', 75% were aged between 21-35 years old. Infants' presenting with sepsis were followed 
up for 60 days of life. Onset of sepsis was recorded, early onset (EOS) <72h, and late onset (LOS) >72h.
Recruitment BARNARDS recruited from 12 clinical sites from Rwanda, Bangladesh, Ethiopia, Nigeria, Pakistan, India and South Africa. 
Where possible, large public hospitals were chosen.  
 
Following the presentation of information regarding the study, mothers in labour were enrolled into the study. Consent was 
collected by trained research staff and using local languages. Corresponding neonates presenting with clinical signs of sepsis 
were then enrolled into the study.  
Additionally, neonates not born within the clinical sites that were admitted with clinical signs of sepsis were also enrolled into 
the study following consent from the mother. The corresponding mothers were also enrolled into the study for the collection 
of demographic data. 
Neonatal follow-up was carried out at day 3, 7, 14, 28, and 60 by research nurses either face-to-face or by telephone. 
Neonates remained in the study until 60 days old, withdrawal, or death.  
This study incorporated two recruitment pathways to include both neonates born within the clinical sites, and also neonates 
in the larger catchment areas presenting to the hospital with signs of sepsis.  
Ethics oversight Site  committees Named PI Reference(s) Approval date(s) 
BC - Ethical Review Committee, Bangladesh Institute of Child Health Samir Kumar Saha BICH-ERC-4/3/2015 15/09/2015 
BK - Ethical Review Committee, Bangladesh Institute of Child Health Samir Kumar Saha BICH-ERC-4/3/2015 15/09/2015 
ES - Boston Children's Hospital Grace Chan IRB-P00023058 11/08/2016 
IN - Institutional Ethics Committee, National Institute of Cholera and Enteric Diseases and Institue of Post Graduate Medical 
Education and Research, IPGME&R Research Oversight Committee Sulagna Basu A-I/2016-IEC and Inst/IEC/2016/508 
17/11/2016 and 04/11/2016 
NK - Kano State Hospitals Management Board Kenneth Iregbu 8/10/1437AH 13/07/2016 
NN - Health Research Ethics Committee (HREC), National Hospital, Abuja Kenneth Iregbu NHA/EC/017/2015 27/04/2015 
NW - Health Research Ethics Committee (HREC), National Hospital, Abuja Kenneth Iregbu NHA/EC/017/2015 27/04/2015 
PC - Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences (PIMS) Islamabad Rabaab Zahra 
NA, signed letter from Prof. Tabish Hazir 27/05/2015 
PP - Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences (PIMS) Islamabad Rabaab Zahra 
NA, signed letter from Prof. Tabish Hazir 27/05/2015 
RK - Republic of Rwanda, National Ethics Committee Jean-Baptiste Mazarati No342/RNEC/2015 10/11/2015 
RU - Republic of Rwanda, National Ethics Committee Jean-Baptiste Mazarati No342/RNEC/2015 10/11/2015 
ZAT - Stellenbosch University and Tygerberg Hospital, Research projects, Western Cape Government Shaheen Mehtar 
N15/07/063 04/12/2015 and 02/02/2016
Note that full information on the approval of the study protocol must also be provided in the manuscript.
